Tech Center 1600 • Art Units: 1637 1646
This examiner grants 0% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18244577 | Treatment Of Endometriosis With R-Spondin 3 (RSPO3) Inhibitors | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18498834 | USING siRNAs AGAINST TAU CIRCULAR RNAS AS A RATIONAL THERAPY FOR ALZHEIMER'S DISEASE | Non-Final OA | University of Kentucky Research Foundation |
| 18251384 | ENHANCEMENT OF PREDICTABLE AND TEMPLATE-FREE GENE EDITING BY THE ASSOCIATION OF CAS WITH DNA POLYMERASE | Non-Final OA | New York University |
| 18278196 | COMPOSITIONS AND METHODS FOR CHARACTERIZING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH MULTIPLE ORGAN FAILURE | Non-Final OA | Arizona Board of Regents on Behalf of the University of Arizona |
| 18079064 | CARDIOVASCULAR IMPLANT BASED ON IN-SITU REGULATION OF IMMUNE RESPONSE AND METHOD FOR MAKING THE SAME | Non-Final OA | Army Medical University |
| 18295036 | SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING | Non-Final OA | Wisconsin Alumni Research Foundation |
| 18265756 | STABLE TARGET-EDITING GUIDE RNA TO WHICH CHEMICALLY MODIFIED NUCLEIC ACID IS INTRODUCED | Non-Final OA | DAIICHI SANKYO COMPANY, LIMITED |
| 18484001 | MICRORNA COMPOSITIONS AND METHODS OF USE THEREOF FOR THE TREATMENT OF NERVOUS SYSTEM DYSFUNCTION | Non-Final OA | Rutgers, The State University of New Jersey |
| 18263194 | COMPOUNDS AND METHODS FOR MODULATING HUNTINGTIN | Non-Final OA | Ionis Pharmaceuticals, Inc. |
| 18361221 | PREVENTION AND TREATMENT OF AGE-RELATED MACULAR DEGENERATION THROUGH SUPPRESSION OF CATHEPSIN S EXPRESSION | Non-Final OA | CHUNG-ANG UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18260456 | METHODS AND COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY | Non-Final OA | Sardocor Corp. |
| 18269793 | Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN, and PLOD1 genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-COL1A1, or Escherichia coli strain SCS110-AF/VTvaf17-COL1A2, or Escherichia coli strain SCS110-AF/VTvaf17-P4HA1, or Escherichia coli strain SCS110-AF/VTvaf17-P4HA2, or Esch | Non-Final OA | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTJU "PRORYVNYE INNOVATSIONNYE TEKHNOLOGII" |
| 18267885 | RNAI AGENT FOR INHIBITING HBV EXPRESSION AND USE THEREOF | Non-Final OA | OliX Pharmaceuticals, Inc. |
| 18036594 | NOVEL STEROID HORMONE LIGAND ASSAYS | Non-Final OA | InsituGen Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy